|
Match
|
Document |
Document Title |
|
|
US20090291050 |
PARTICULATE MATERIALS
Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing the particles...
|
|
|
US20090260271 |
Visible animal scent and dispersion system
An animal scent composition contains animal generated scents and a visual indicator to allow visualization of scent travel and application. The scent may be used for repelling wild and domestic...
|
|
|
US20090258040 |
STEROID TREATMENT FOR HOT FLASHES
Embodiments of the invention relate to methods for treating individuals suffering from hot flashes by vomeronasally administering a therapeutically effective dosage of a steroid agent. The hot...
|
|
|
US20090238772 |
METHODS AND COMPOSITIONS FOR PREVENTION OR TREATMENT OF RSV INFECTION
Methods and compositions are provided for the prevention or treatment of RSV infection in a human. The methods include administering one or more doses of a composition comprising an siRNA. The dose...
|
|
|
US20090220581 |
METHODS OF REDUCING INFLAMMATION AND MUCUS HYPERSECRETION
Methods and compounds for decreasing MARCKS-related inflammation and MARCKS-related mucus hypersecretion or decreasing MARCKS-related inflammation in a subject by the administration of a N-terminal...
|
|
|
US20090110647 |
METHOD OF PREVENTING ADVERSE EFFECTS BY GLP-1
A method for preventing or reducing adverse effects such as profuse sweating, nausea and vomiting, which normally are associated with subcutaneous and intravenous administration of glucagon-like...
|
|
|
US20090098209 |
PHARMACEUTICAL COMPOSITIONS CONTAINING WATER-SOLUBLE DERIVATIVES OF PROPOFOL AND METHODS OF ADMINISTERING SAME VIA PULMONARY ADMINISTRATION
The present invention is directed to methods of delivering propofol derivative compounds via pulmonary administration to a mammal in order to induce or maintain anesthetized, sedated and...
|
|
|
US20090081302 |
PULMONARY DELIVERY OF POLYENE ANTIFUNGAL AGENTS
The present invention provides spray-dried polyene compositions for oral inhalation to the lung. The polyene antifungal compositions demonstrate superior aerosol properties, do not exhibit...
|
|
|
US20090041682 |
MEDICAL PRODUCT
The invention discloses a medical product for use in a treatment of respiratory disorders, and comprises a metered dose of a tiotropium dry powder formulation, directly loaded and sealed into a...
|
|
|
US20090022671 |
TREATMENT METHODS
Disclosed are methods of treating rhinosinusitis of the upper airway passages in patients afflicted with said disease, which comprises administering at least once-a-day to the surfaces of said...
|
|
|
US20080317862 |
Organic Compounds Comprising a Glycopyrrolium Salt
Medicaments comprising (A) an antimuscarinic agent and (B) a corticosteroid for the treatment of inflammatory or obstructive airways diseases.
|
|
|
US20080292563 |
Inhalable Powder Containing Tiotropium
The invention relates to powdered preparations containing tiotropium for inhalation, processes for preparing them as well as their use in preparing a pharmaceutical composition for the treatment of...
|
|
|
US20080292562 |
Medicaments For Inhalation Comprising Pde IV Inhibitors and Enantiomerically Pure Glycopyrrolate Salts
The present invention relates to novel pharmaceutical compositions based on PDE IV inhibitors (2) and salts of formula (1) wherein X may have the meanings defined in the description and claims, and...
|
|
|
US20080286363 |
Pharmaceutical Compositions for the Treatment of Inflammatory and Obstructive Airways Diseases
A medicament comprising, separately or together (A) a compound of formula I
in free or salt or solvate form, (B) a glycopyrronium salt; and (C) a compound of formula II
for simultaneous,...
|
|
|
US20080260657 |
Process for Milling Poorly Soluble Drugs in Presence of Liquid Propellants
Drug substance for use in a pharmaceutical formulation may be prepared by a process which process comprises co-milling a suspension of the drug substance and a pharmaceutically acceptable polymer...
|
|
|
US20080253971 |
Particles for inhalation having sustained release properties
The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to...
|
|
|
US20080226564 |
Respiratory dispersion for metered dose inhalers
A respiratory dispersion is provided for the pulmonary delivery of at least two bioactive agents. The dispersion comprises a propellant suspension medium having dispersed therein a plurality of...
|
|
|
US20080175797 |
PREVENTING AIRWAY MUCUS PRODUCTION BY ADMINISTRATION OF EGF-R ANTAGONISTS
Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic...
|
|
|
US20080160098 |
USE OF SIMPLE AMINO ACIDS TO FORM POROUS PARTICLES
Particles having a tap density of less than 0.4 g/cm 3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred...
|
|
|
US20080138399 |
DUAL RELEASE NICOTINE FORMULATIONS, AND SYSTEMS AND METHODS FOR THEIR USE
This invention relates generally to a method to provide habitual tobacco users with products, methods and apparatus to reduce and eventually terminate their dependence on nicotine containing...
|
|
|
US20080131377 |
Pharmaceutical Aerosol Compositions
An aerosol formulation comprising a biodegradable microsphere comprising a non-living reagent, such as a sub-unit vaccine, that produces a protective immune response in a mammal to whom it is...
|
|
|
US20080118442 |
Aerosol Formulations for Delivery of Dihydroergotamine to the Systemic Circulations Via Pulmonary Inhalation
Pharmaceutical aerosol formulations of dihydroergotamine, or pharmaceutically acceptable salts thereof, to administer dry powders and propellant suspensions via pulmonary aerosol or nasal spray...
|
|
|
US20080112896 |
Therapeutic Compositions for Pulmonary Delivery
Microparticles that are obtainable by spray-freeze-drying a solution comprising a water-soluble, matrix-forming polymer and a therapeutic agent may be useful for pulmonary delivery of the...
|
|
|
US20080112895 |
Aqueous dronabinol formulations
A room temperature stable aqueous cannabinoid formulation is disclosed. In preferred embodiments, the cannabinoid formulation comprises dronabinol in a mixture of buffer solution, and organic...
|
|
|
US20080107609 |
PULMONARY DISEASE TREATMENT
The invention relates to treating chronic obstructive pulmonary disease, involving the administration by inhalation of mometasone furoate particles in daily doses where at least about 250 μg of...
|
|
|
US20080102040 |
INHIBITION OF FACTOR B, THE ALTERNATIVE COMPLEMENT PATHWAY AND METHODS RELATED THERETO
Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway...
|
|
|
US20080095718 |
METHODS AND COMPOSITIONS FOR TREATING ERECTILE DYSFUNCTION
Methods are provided for increasing libido and/or treating erectile dysfunction in a man. The methods include the administration of a formulation testosterone alone, another fast-acting drug to...
|
|
|
US20080089849 |
POWDERS FOR INHALATION
The invention therefore relates to protein-containing powders, wherein the proportion of phenylalanine is at least 30% (w/w), or at least 40% (w/w). It has been shown that phenylalanine-containing...
|
|
|
US20080066744 |
PROCESS FOR PRODUCING METERED DOSE INHALER FORMULATIONS
Disclosed are methods of introducing a suspension or solution of a medicament, preferably mometasone furoate anhydrous, into a metered dose inhaler container, said container having a valve attached...
|
|
|
US20080063608 |
Pharmaceutical Compositions for Inhalation Containing an Anticholinergic, Corticosteroid, and Betamimetic
A pharmaceutical composition comprising:
(a) an anticholinergic of formula 1
wherein X − is an anion with a single negative charge; (b) a corticosteroid; and (c) a betamimetic,...
|
|
|
US20080057004 |
ALBUMIN-INSULIN FUSION PROTEINS
Disclosed are fusion proteins that include albumin fused to a polypeptide that has insulin activity. The fusion proteins may include albumin fused to insulin or an insulin analog. In particular,...
|
|
|
US20080057003 |
Powder inhaler formulations
The present invention relates to new methods for the surface modification of powders. Furthermore the present invention relates to new, improved pharmaceutical dosage forms obtainable by the new...
|
|
|
US20080047550 |
SUBLINGUAL DRUG DELIVERY DEVICE
A drug delivery device that aerosolizes a dry powder formulation so that it forms a fine coating in the oral cavity and, more specifically in the sublingual region of the oral cavity is described...
|
|
|
US20080038357 |
Inhalation Powder Containing the CGRP antagonist BIBN4096 and Process for the Preparation Thereof
The invention relates to an inhalation powder for treating migraine, containing the CGRP antagonist 1-[N 2...
|
|
|
US20080031828 |
Method for the Treatment of Dyspnea Comprising Combined Administration of Tiotropium Salts and Salts of Salmeterol
|
|
|
US20080003294 |
Methods for pulmonary delivery of interleukin-2
Methods for administering interleukin-2 (IL-2) or variants thereof via pulmonary inhalation are provided. The methods comprise preparing a pharmaceutical composition comprising IL-2 or variants...
|